Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.

Human vaccines - 1 Aug 2011

van der Ley Peter, van den Dobbelsteen Germie

Abstract excerpt

Outer membrane vesicles (OMVs) have been used extensively as experimental vaccines against Neisseria meningitidis. Classical meningococcal OMV vaccines contain wildtype lipopolysaccharide (LPS) with a hexa-acylated lipid A moiety, which is a very potent activator of the TLR4 receptor. While this may make the LPS an effective "internal" adjuvant, it also contributes to vaccine reactogenicity. Reduction of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyltransferases
Share to Antibodies, Bacterial
Share to Bacterial Outer Membrane Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bacterial Proteins

Share to Lipopolysaccharides

Share to Meningococcal Vaccines

Share to Neisseria meningitidis

Share to Vaccines, Synthetic

Source

Identifiers

PMID: 21785281
DOI: 10.4161/hv.7.8.16086

Genes

TLR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.PMID 21785281Read ↗

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.Semantic proximity Read ↗

Outer Membrane Vesicle Vaccine PlatformsSemantic proximity Read ↗

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.Semantic proximity Read ↗

Outer membrane vesicles as platform vaccine technologySemantic proximity Read ↗

Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.Semantic proximity Read ↗

Genetically Modified L3,7 and L2 Lipooligosaccharides from Neisseria meningitidis Serogroup B Confer a Broad Cross-Bactericidal ResponseSemantic proximity Read ↗

Lipopolysaccharide: a tool and target in enterobacterial vaccine development.Semantic proximity Read ↗

Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strainsSemantic proximity Read ↗

Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles.Semantic proximity Read ↗

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccineSemantic proximity Read ↗

Novel approaches to Neisseria meningitidis vaccine designSemantic proximity Read ↗

Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.